郭军

 

    郭 军:男,1966年11月出生,医学博士,主任医师,副教授,现任北京肿瘤医院肾癌黑色素瘤内科主任,中国临床肿瘤协会(CSCO)执委会委员,中国临床肿瘤学会(CSCO)黑色素瘤专家委员会主任委员, 国际黑色素瘤研究联盟(Society for Melanoma Research)常务委员,国际黑色素瘤监督委员会候补委员,全球黑色素瘤专家委员会GMTF(Golbal Melanoma Task Force)委员,黑色素瘤国际基金会(MIF)海外咨询顾问,中国抗癌协会泌尿肿瘤分会常务委员,中华医学会«中国肾癌诊治指南»编写组成员,«NCCN肾癌诊治指南中国版»执笔人,«中国黑色素瘤诊治共识»编写组执笔人。国家教育部 “新世纪优秀人才支持计划”入选者,北京市“十百千”卫生优秀人才基金获得者,新世纪百千万人才工程北京市级人选。

    1990年西安第四军医大学医疗系六年制本科毕业,1995年于第四军医大学唐都医院获医学硕士学位,2001年于上海第二军医大学获免疫学博士学位。长期从事肿瘤临床及科研工作,主要研究方向为恶性肿瘤的生物免疫治疗,尤其在恶性黑色素瘤和肾癌的治疗方面有较独特的研究并积累了较丰富的临床经验。

    曾获国家专利一项、省级科技进步二等奖二项、军队科技进步三等奖2项、四等奖一项。在国际著名医学杂志上(Blood, Gene Ther, Int J Cancer等)发表论著10余篇,在国内核心期刊发表论著20余篇。编译并出版了«黑色素瘤的预防诊断与治疗»一书。作为项目负责人,承担国家自然科学基金、国家教育部“985”工程等多项基金课题。

    专业特长: 恶性黑色素瘤、肾癌及前列腺癌的化疗和生物免疫治疗

    出诊时间: 周三下午 周五上午

Jun Guo, MD, PhD
Department of Renal Cancer and Melanoma,
Peking University School of Oncology,
Beijing Cancer Hospital,
52 Fucheng Road, Hai-dian District,
Beijing 100036,
PR China.
Phone: 86-10-88196317
Fax: 86-10-881196317
E-mail: guoj307@126.com.

Experimental and Clinical Treatment of Melanoma and Renal Cancer

I am an oncologist from China. I have experienced clinical work for more than 15 years. Since 1990, I have focused on the treatment of cancer, especially on Melanoma and Renal cancer. Over the past years of my career, the greatest honor is the smiles of my patients, the greatest happiness is the hope I give to my patients, and the greatest pain is the vanishing of the fresh life of my patients. My Education and Working Experience

I was born in the Inner Mongolia Province of China, a place famous for peaceful and boundless grasslands as well as brave and husky historical heroes. I received my primary medical bachelor education between 1984 and 1990 in the Fourth Military Medical University in Xi’an of Shanxi Province, an ancient city representing the splendid and brilliant history of China. In 1995, I got my Master degree in Xi’an after a three-year-study. To extend my understanding of tumor immunology, I received my doctor degree between 1999 and 2002 in Institute of Immunology, Second Military Medical University in Shanghai of China.

My first clinical practice of cancer treatment began in 1990 when I worked as a physician in Department of Clinical Oncology, Jinan General Military Hospital, Shandong Province. I worked there for six years. I obtained my backgroud exprience in chemotherapy and radiotherapy of cancer. However, I became to realize that the combat against cancer need more overall and comprehensive therapeutics. In 2002, I began to work in Beijing Cancer Hospital and established the Department of Melanoma and Renal Cancer. Therein, I began to practice immunotherapy of advanced melanoma and renal cancer in combination with the traditional chemotherapy and radiotherapy.

These experiences have provided me with knowledge in molecular and cellular immunology and with systemic training in both experimental and clinical cancer treatments.

My Research Interests and Experiences< I was interested in Oncology. During the past years, my reseach interests have spanned several tumor-accociated hot spots, including chemokine and chemokine receptors, the development of tumor vaccines and the cancer targeted therapies.

A major part of my studies is about chemokines and chemokine receptors. I have studied the mechanisms of utilization of MDC/CCL22 and fractalkine/CX3CL1 in cancer therapy in mouse model. We found that these chemokines could elicit therapeutic effects and induce tumor-specific antitumor immunity via chemoattracting, adhering or activating immune cells, such as dendritic cells (DC), T cells and natural killer cells (NK). My another work about chemokine/chemokine receptor, however, was less closely related to tumor immunology, which for the first time showed that cyclosporin A could inhibit the migration of DC by inhibiting the CCR7 and cyclooxygenase expression and that cyclosporin A could synergize with prostaglandin E2 to induce the recurrence of tumor by imparing the function of DC.

I have also devoted myself to the development of cancer vaccines. Exosomes have been reparded as a kind of cell-free cancer vaccine. My doctoral thesis researched the exosomes derived from heat-shocked tumor cells in 2000. I found that exosomes derived from heat-shocked tumor cells could elicit more potent antitumor immunity than traditional exosomes by expressing chemokines and higher level of heat shock proteins (HSP).

The most impartant clinical trials of immunotherapy in my department is the utilization of DC in melanoma and renal cancer treatment. I, together with my staff, performed a phaseⅠ-Ⅱ Clinical Trial of combinating intratumoral injection of immature dendritic cells (IT-DC) with local hyperthermia (LHT) in patients with advanced melanoma or renal cancer. Our trials in melanoma patients showed that IT-DC in combination with LHT could induce systemic melanoma-specific antitumor immunity in patients possibly by enhancing the expression of HSP by tumor cells, altering and chemokine pattern of the tumor microenvironment, decreasing the infiltrating regulatory T cells (Treg) in tumors and promoting the migration of DC to second lymph nodes.

Our team has conducted the firist Clinical Trial of The Efficacy and Safety of Subcutaneous Proleukinâ in Chinese Patients With Metastatic Renal Cell Carcinoma. The study included 41 patients who were diagnosed as having metastatic RCC following radical nephrectomy This study confirmed that subcutaneous recombinant human interleukin-2 treatment can benefit some Chinese patients with metastatic renal cell carcinoma by producing durable responses and survival time. During the trial severe toxicities(grade ≥3) were unusual, and Chinese patients can tolerate rhIL-2 therapy.

The experimental research of cancer can give me creative idea for the developing novel therapeutics. My clinical experience of cancer may provide the opportunity to introduce the most safe and effective experimental treatments to my patients. A better bidge between the experimental studies and clinical trials will endow the patients with hope and confidence in fighting the cancer.

My Challenges and Hopes China is an ancient country with large populations. Cancer has threatened a larger arbitrary numbers of people than the other parts of the world. However, the studies of cancer in China has lagged behind the trend of world for many years. Cancer itself is a devil that need the combining effort of all scientists around the world. Melanoma and Renal cancer are less frequent cancer types in China than other high risk cancers such as lung cancer, colon cancer and breast cancer. Our department is the unique unit specified in melanoma and renal cancer in China. Development of novel thrapeutics and introduction of more efficient treatments to our patients are the greatest challenges for me and my staff.

With the better and better understanding of molecular mechanisms in tumorigenesis and tumor escape, the treatment of cancer becomes more and more promising, though with difficulties and puzzles ahead. DC vaccines, utilization of chemokines and cytokines, elimination of Treg cells etc. have casted new light on the cancer treatments. I believe that scientific reasearch and trials will bring promise and hope to all the patients suffering from cancer.

By far, the best part of my job is my work with my patients. I -- along with the rest of my staff -- understand how important it is to take time to talk with our patients about complicated procedures and treatment plans.

The best part of my work is developing new treatments that can help patients live productive, fulfilling lives. It’s a great feeling to have options to offer patients and to give them hope.

My Publications Guo J, Zhu J, Sheng X, Wang X, Qu L, Han Y,Liu Y, Zhang H, Huo L, Zhang S, Lin B, Yang Z. Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Int J Cancer. 2007 Feb 9; [Epub ahead of print]

Chen T, Guo J, Yang M, Han C, Zhang M, Chen W, Liu Q, Wang J, Cao X. Cyclosporin A impairs dendritic cell migration by regulating chemokine receptor expression and inhibiting cyclooxygenase-2 expression. Blood. 2004 Jan 15;103(2):413-21.

Zhang M, Tang H, Guo Z, An H, Zhu X, Song W, Guo J, Huang X, Chen T, Wang J, Cao X. Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells.Nat Immunol. 2004 Nov;5(11):1124-33

Guo J, Zhang M, Wang B, Yuan Z, Guo Z, Chen T, Yu Y, Qin Z, Cao X. Fractalkine transgene induces T cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells. Int J Cancer 2003, Jan; 130(2):213-220

Guo J, Chen T, Wang B, Zhang M, An H, Guo Z, Yu Y, Qin Z, Cao X. Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. Immu Lett 2003 Oct 9;89(1):1-7.

Guo Z, Zhang M, An H, Chen W, Liu S, Guo J, Yu Y, Cao X. Fas ligation induces IL-1beta-dependent maturation and IL-1beta-independent survival of dendritic cells: different roles of ERK and NF-kappaB signaling pathways. Blood. 2003 Dec 15;102(13):4441-7.

Chen T, Han Y, Yang M, Zhang W, Li N, Wan T, Guo J, Cao X. Rab39, a novel Golgi-associated Rab GTPase from human dendritic cells involved in cellular endocytosis. Biochem Biophys Res Commun. 2003 Apr 18;303(4):1114-20.

Guo J, Wang B, Zhang M, Chen T, Yu Y, Regulier E, Homann HE, Qin Z, Ju DW, Cao X. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther 2002 9(12):793-803